Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting

GlobeNewswire May 15, 2020

Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

GlobeNewswire May 15, 2020

Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

GlobeNewswire May 14, 2020

Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress

GlobeNewswire May 7, 2020

Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7

GlobeNewswire May 1, 2020

Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia

GlobeNewswire April 16, 2020

Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress

GlobeNewswire March 3, 2020

Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 25, 2020

Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3

GlobeNewswire February 24, 2020

Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

GlobeNewswire January 30, 2020

Autolus Announces Closing of Public Offering

GlobeNewswire January 27, 2020

Autolus' Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting

GlobeNewswire January 27, 2020

Autolus Announces Pricing of Public Offering

GlobeNewswire January 22, 2020

Autolus Announces Proposed Public Offering in the United States

GlobeNewswire January 22, 2020

Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference

GlobeNewswire January 13, 2020

Autolus Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 20, 2019

Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting

GlobeNewswire December 5, 2019

Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

GlobeNewswire November 13, 2019

Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

GlobeNewswire November 13, 2019

Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

GlobeNewswire November 9, 2019